Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III

Author: Aviva Lev-Ari, PhD, RN

 

Distinction between A and B, below

• A.  1.0 LPBI – 2012–2020 – IP Assets available for sale

• B.  2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE

 

A.  1.0 LPBI – 2012–2020 – IP Assets available for sale

 

A.1 A List of Scientific articles N=6,000 

STORED in Excel file run on 6/30/2020 and 12/31/2020

 

They need to be Indexed by several keys:

A.1.1  Author Name

A.1.2  Article Title

A.1.3  Category of Research, see article example , below

For the Cancer category

• we have the following tree structure
• System had data on how many articles are in each category

•  Cancer – General
•  Cancer and Current Therapeutics
  •  interventional oncology
    •  Breast Cancer – impalpable breast lesions
    •  Prostate Cancer: Monitoring vs Treatment
•  CANCER BIOLOGY & Innovations in Cancer Therapy
  •  Anaerobic Glycolysis
  •  Cachexia
  •  Cancer Genomics
    •  Circulating Tumor Cells (CTC)
      •  Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood
        •  mRNA
      •  MagSifter chip
    •  KRAS Mutation
    •  Li-fraumeni syndrome.
    •  TP53 – Germline mutations
  •  cancer metabolism
  •  Funding Opportunities for Cancer Research
  •  Genomic Expression
  •  Glioblastoma
  •  Hexokinase
  •  Loss of function gene
  •  Metabolic Immuno-Oncology
  •  Metastasis Process
  •  Methylation
  •  Microbiome and Responses to Cancer Therapy
  •  Monoclonal Immunotherapy
  •  mtDNA
  •  Oxidative phosphorylation
  •  Pancreatic cancer
  •  Pyruvate Kinase
  •  The NCI Formulary
  •  tumor microenvironment
  •  Warburg effect
•  Cancer Informatics
•  Cancer Prevention: Research & Programs
•  Cancer Screening
•  Cancer Vaccines: Targeting Cancer Genes for Immunotherapy
  •  Engineering Enhanced Cancer Vaccines

A.1.4  Type of article: by the role of the author: 

• If the Author is Curator THAN this article is a curation
• If the Author is Reporter THEN this article is a Scientific reporting article

A.1.5  Article Abstract will be a WordCloud created by ML – one image per article

Example

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?  <<<<<<<<< Article Title

Author: Larry H. Bernstein, MD, FCAP  <<<<<<<<< Author’s Name

https://pharmaceuticalintelligence.com/2012/10/17/is-the-warburg-effect-the-cause-or-the-effect-of-cancer-a-21st-century-view/   <<<<<<< URL

• The system provides: “Related” what you named associated, see below – will need to be placed in the article description
• The system provides: “Posted in” – meaning – ALL the categories of research checked off by the author that this article belong to by the SUBJECT MATTER of the article

EXAMPLE for “Related” what you named associated

Related

What can we expect of tumor therapeutic response?

In “Biological Networks, Gene Regulation and Evolution”

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

In “Academic Publishing”

AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo

In “Biological Networks, Gene Regulation and Evolution”

Examples for >>>>>>>> Category of Research – live links listing in parenthesis number of articles in one category

Posted in Biological Networks, CANCER BIOLOGY & Innovations in Cancer Therapy, Cell Biology, Disease Biology, Genome Biology, Imaging-based Cancer Patient Management, International Global Work in Pharmaceutical, Liver & Digestive Diseases Research, Metabolomics, Molecular Genetics & Pharmaceutical, Nutrition, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Population Health Management, Proteomics, Stem Cells for Regenerative Medicine, Technology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphate, ATP, Glycolysis, Hypoxia-inducible factors, Kreb, Lactate dehydrogenase, Mammalian target of rapamycin, Mitochondrion, Warburg Effect | 40 Comments

Below, an excerpt from the 6,000 LIST: Top Posts by VIEWS for all days ending 2020-06-02 (Summarized)

 

All Time
Title	Views	Author Name	Type of Article
Home page / Archives	676,690	Internet Access	Tabulation
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?	17,117	Larry H. Bernstein, MD, FACP	Investigator Initiated Research
Recent comprehensive review on the role of ultrasound in breast cancer management	14,242	Dr. D. Nir	Commission by Aviva Lev-Ari, PhD, RN
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)	13,839	Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN	Commission by Aviva Lev-Ari, PhD, RN
Paclitaxel vs Abraxane (albumin-bound paclitaxel)	13,709	Tilda Barliya, PhD	Investigator Initiated Research
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications	8,230	Aviva Lev-Ari, PhD, RN	Investigator Initiated Research
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care	7,903	Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN	Investigator Initiated Research
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)	6,540	Tilda Barliya, PhD	Investigator Initiated Research
Our TEAM	6,505	Internet Access	Tabulation
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects	5,221	Larry H. Bernstein, MD, FACP	Investigator Initiated Research
Interaction of enzymes and hormones	4,901	Larry H. Bernstein, MD, FACP	Commission by Aviva Lev-Ari, PhD, RN
Akt inhibition for cancer treatment, where do we stand today?	4,852	Ziv Raviv, PhD	Investigator Initiated Research
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation	4,535	Stephen J. Williams, PhD	Investigator Initiated Research
The History and Creators of Total Parenteral Nutrition	4,511	Larry H. Bernstein, MD, FACP	Commission by Aviva Lev-Ari, PhD, RN
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses	4,365	Zohi Sternberg, PhD	Investigator Initiated Research
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules	4,188	Stephen J. Williams, PhD	Investigator Initiated Research
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets	4,038	Dr. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FACP & Aviva Lev-Ari, PhD, RN	Commission by Aviva Lev-Ari, PhD, RN
Founder	3,895	Aviva Lev-Ari, PhD, RN	Investigator Initiated Research

EndFragment

A.2 A List of 16 e-BOOKS

https://lnkd.in/ekWGNqA

 

A.2.1   Each book is made of articles included in the N=6,000

A.2.2 Books will list the URL of each book

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

https://www.amazon.com/dp/B07MGSFDWR

https://www.amazon.com/dp/B07MKHDBHF

https://www.amazon.com/dp/B08385KF87

A.3 A List of e-Proceedings and Tweet Collections

• Part Two: List of BioTech Conferences 2013 to Present
• Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

A.3.1 each entry is an article included in N=6,000

B.   2.0 LPBI – 2021–2025 –

IP Assets under construction –

WILL BE AVAILABLE FOR SALE

 

B.1 Journal articles

• Will be subjected to ML and a NEW product will be created
• Instead of N=6,000 article – we will have N= 6,000 Medical INSIGHTS

B.2 16 e-Books

• Will be subjected to ML and a NEW product will be created
• Instead of 16 Books – we will have 16 COLLECTIONS of Medical INSIGHTS derived from Text Analysis of ONLY the articles included on each Volume
• 16 e-Books will become 16 AUDIO BOOKS
• 16 e-Books will become 16 Books in Japanese, Spanish and Russians

 

B.3 eProceedings & Tweet collections

• Will be subjected to ML and a NEW product will be created
• Instead of 60 e-Proceedings and 30 Tweet collections we will get 100 Business INSIGHTS Collections in the domain of each conference

 

We believe that Blockchain will enable STORAGE of each item that will be available for sale

• LPBI will have team members Bundling items per customer needs 
• Promotion can be done OUTSIDE the Blockchain system – STIRRING Customers to the Blockchain transaction system for TRADE and recording of transactions
• That is true for A and for B, below

A.   1.0 LPBI – 2012–2020 – IP Assets available for sale

B.   2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE

 

Data Architecture Questions

 

1. In what data format is the content stored? In other words, is the content in image pdfs, searchable document pdfs, html, xls, word documents, text files, or some other form?

Example: TEXT

Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words

• Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

My proposed Elevator Pitch

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers ~6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 16 books have been downloaded ~125,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

• • We UPLOAD MS Word file NOT PDF
  • INVENTORY is stored in Excel
  • Top Posts for all days ending 2020-11-16 (Summarized)
    1. 7 Days |30 Days |Quarter |Year |All time
  • All Time

Title		Views
Home page / Archives		716,030
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?		17,263
Recent comprehensive review on the role of ultrasound in breast cancer management		15,300
Paclitaxel vs Abraxane (albumin-bound paclitaxel)		14,341
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)		14,006
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications		8,770
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care		8,398
Our TEAM		6,632
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)		6,580
Interaction of enzymes and hormones		5,536
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects		5,304
The History and Creators of Total Parenteral Nutrition		5,056
Akt inhibition for cancer treatment, where do we stand today?		4,899
Pyrroloquinoline quinone (PQQ) – an unproved supplement		4,712
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation		4,665
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses		4,453
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules		4,416
Evolution of Myoglobin and Hemoglobin		4,335
Isoenzymes in cell metabolic pathways		4,206
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets		4,126
Founder		4,118

2. Within each content file or dataset, is the content metadata already defined, or would we need to parse the file to pull out the metadata? In other words, in the file for a journal article, do you already have the author, date, abstract, keywords, etc. defined as discrete pieces of data, or is all of this information embedded within the overall file?

YES

They need to be Indexed by several keys:

A.1.1  Author Name

A.1.2  Article Title

A.1.3  Category of Research

 

3. Do you expect to use a single type of subscription (such as a monthly subscription), or will different types of data have different types 

of subscription options (similar to how journals offer both one-time 24-hour subscriptions to a single article as well as monthly ongoing subscriptions)?

We wish to SELL ARTICLE DOWNLOAD vs Subscriptions

4. Does the marketplace need to include fuzzy search (i.e., the ability to find content based on “similar to” criteria, instead of just exact match searches)? Does it need to present the user with related content, or only the content that was searched for?

Our system attaches to each article RELATED content

5. We assume that the marketplace is not intended to replace your current LPBI company website? We are not scoping the quote to include a full website rebuild; it is assumed that the marketplace is separate (and your users would access the marketplace via the LPBI website).

YES – the digital store will connect to our newly to be designed web site for 2.0 LPBI on WordPress.com

• The digital store is the FORUM to buy goods by digital download of content
• $30 for One digital article or Audio article
• REFERRAL to Amazon Website to buy a book or the book in AUDIO format or a book in Japanese and Spanish – Russia is not served by Amazon – we can sell directly to consumers
• $100 download of an e-Proceedings for a Conference or the Tweet collection

For 2.0 LPBI Products

Bundles of Insights for Targeted Industries – B–to-B

• Tier #1:  Insights for drug discovery embedded in consulting engagements
• Tier #2:  Insights for drug repurposing embedded in consulting engagements
• Tier #3:  Insights for Health Care Insurers embedded in consulting engagements

Bundles of insights for theScientific Community – B–to-C